Skip to Main Content

Paper Details

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Clin Cancer Res
27
2022
ER, ER+/HER2mut MBC, ER-negative (ER-)/HER2mut MBC, Fulvestrant, HER2, HER2 L755, HER2-Mutated, Non-amplified Metastatic Breast Cancer, HER2mut, HER2mut MBC, L755, MBC, MutHER, Neratinib, Patients, estrogen, estrogen receptor, estrogen receptor-positive (ER+) breast cancer, fulvestrant, metastatic breast cancer, neratinib, patients, trastuzumab
Author NameAffiliation
Cynthia X MaWashington University School of Medicine
Cynthia X MaSiteman Cancer Center
Julie NangiaDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Nancy U LinDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
Paul K MarcomDuke Cancer Institute
Lisa A CareyUniversity of North Carolina
Matthew P GoetzMayo Clinic
Matthew J EllisBaylor College of Medicine
Ron BoseWashington University School of Medicine
Ron BoseSiteman Cancer Center
  • 1 - 11

Datasets

Release 1.2